Table 2 Summary of the reported case series of co-existence of PTC and FTC
From: Collision tumor of a papillary and follicular thyroid carcinoma: a case report
Case No | Author | Age (years) | Sex | Size, location of PTC | Size, location of FTC | Lymph node metastasis | Distant metastasis | Immunohistochemistry | Genetic analysis | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Plauche V, et al. [2] | 62 | F | multifocal, largest 1 cm, left lobe | 4.1 cm, left lobe and 0.3 cm right lobe | none | none | N/A | N/A | N/A |
2 | Cracolici V, et al. [3] | 63 | F | 1.7 cm, left lobe | 1.1 cm, right lobe | metastasis of PTC | metastasis of FTC to the 11th rib | positive for TTF-1 and thyroglobulin, negative for calcitonin and BRAF | BRAF(V600E) mutation in PTC, NRAS(Q61R) mutation in FTC | liver and T12 metastasis, alive for at least 6 months |
3 | Dai DJ, et al. [4] | 66 | F | 0.5 cm, left lobe | 1.2 cm, right lobe | none | none | N/A | N/A | N/A |
4 | He X, et al. [5] | 71 | M | 0.1 cm, left lobe | 4.8 cm, right lobe | none | metastasis of FTC to right adrenal grand | positive for thyroglobulin | N/A | alive for at least 14 months after thyroidectomy |
5 | Pishdad R, et al. [6] | 79 | M | left / right and size unknown | left / right and size unknown | none | metastasis of FTC to left femur | N/A | no RAS mutation | alive for at least 7 months after treatments |
6 | Abdelaal A, et al. [7] | 31 | F | 5 cm, left lobe | 1.3 cm, left lobe | none | none | N/A | N/A | alive for at least 2 years |
7 | Abdelaal A, et al. [7] | 61 | M | 0.3 mm, right lobe | 6 cm, right lobe | none | none | N/A | N/A | alive for at least 15 months |
8 | Abdelaal A, et al. [7] | 59 | M | 1.5 cm, left lobe or isthmus | 5 cm, left lobe and isthmus | none | none | N/A | N/A | alive for at least 22 months |
9 | Abdelaal A, et al. [7] | 56 | F | multifocal, both lobes, largest 1 cm | 4.5 cm, left lobe | none | none | N/A | N/A | lost to follow-up after surgery |
10 | Abdelaal A, et al. [7] | 35 | F | two foci, largest 0.8 cm, right lobe | 1.3 cm, right lobe | none | none | N/A | N/A | lost to follow-up after treatment |
11 | Abdelaal A, et al. [7] | 52 | F | 0.8 cm, right lobe | 2.7 cm, right lobe | none | none | N/A | N/A | alive, unknown for follow-up period |
12 | Feng JW, et al. [8] | 40 | F | 1.8 cm, right lobe | left lobe, unknown for size | none | none | In FTC, positive for CK19, thyroglobulin, negative for calcitonin, Galectin-3, Chromogranin A, Synaptophysin, CD56 and TIF-1, Ki-67LI was 1% | N/A | alive at least 26 months |
13 | Vlaenderen JV, et al. [9] | 12 | F | several mm, left lobe | 2.9 cm, left lobe | none | none | in PTC, positive for HBME | No mutation is found in BRAF, NRAS, RET/PTC rearrangements, TSHR gene, GNAS gene and PTEN gene | N/A |
14 | Carrion AMS, et al. [10] | 56 | M | 2.5 cm, right lobe | 1.5 cm, left lobe | LN metastasis of PTC | right shoulder bone metastasis | N/A | N/A | N/A |
15 | Stenman A, et al. [11] | 43 | F | 3 cm, right lobe | 1.2 cm, right lobe | central and lateral LN metastasis of PTC, lateral LN metastasis of FTC | none | In PTC, positive for BRAF1, 50% of tumor cells positive for thyroglobulin and Ki-67 LI was 5.6%. in FTC, negative for BRAF1 and Ki-67 LI was 3% | p.Q61R missense NRAS mutation was detected in both primary and LN metastasis of FTC. TERT promoter C228 and C250 were both wild type in FTC | alive, unknown for follow-up period |
16 | Present case | 69 | F | 5.2 cm, right lobe | 4.0 cm, right lobe and isthmus | central and lateral lymph node metastasis of PTC | none | In PTC, positive for TTF-1, thyroglobulin, CK19, HBME-1, Galectin-3 and BRAF (V600E), and the Ki-67LI was 5%. In FTC, positive for TTF-1 and thyroglobulin, and negative for CK19, HBME-1, Galectin-1 and BRAF (V600E), Ki-67 LI was 3% | In PTC, TERT promoter C228T mutation was detected whereas NRAS mutation was not detected. In FTC, TERT promoter mutation was not detected whereas NRAS codon 61 mutation was detected | Died of recurrent tumor 8 months after surgery |